NO20006161D0 - Topisk tilförsel av oksazolidinoner for transdermal levering - Google Patents

Topisk tilförsel av oksazolidinoner for transdermal levering

Info

Publication number
NO20006161D0
NO20006161D0 NO20006161A NO20006161A NO20006161D0 NO 20006161 D0 NO20006161 D0 NO 20006161D0 NO 20006161 A NO20006161 A NO 20006161A NO 20006161 A NO20006161 A NO 20006161A NO 20006161 D0 NO20006161 D0 NO 20006161D0
Authority
NO
Norway
Prior art keywords
topical administration
oxazolidinones
transdermal delivery
infections
bacteremia
Prior art date
Application number
NO20006161A
Other languages
English (en)
Norwegian (no)
Other versions
NO20006161L (no
Inventor
Charles W Ford
Jeffrey L Watts
Original Assignee
Upjohn Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Upjohn Co filed Critical Upjohn Co
Publication of NO20006161L publication Critical patent/NO20006161L/no
Publication of NO20006161D0 publication Critical patent/NO20006161D0/no

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/42—Oxazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/42—Oxazoles
    • A61K31/422—Oxazoles not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/444—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring heteroatom, e.g. amrinone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/16—Otologicals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Pain & Pain Management (AREA)
  • Cardiology (AREA)
  • Rheumatology (AREA)
  • Dermatology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
  • Medicinal Preparation (AREA)
  • Plural Heterocyclic Compounds (AREA)
NO20006161A 1998-06-05 2000-12-04 Topisk tilförsel av oksazolidinoner for transdermal levering NO20006161D0 (no)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US8828398P 1998-06-05 1998-06-05
PCT/US1999/010463 WO1999062504A2 (en) 1998-06-05 1999-05-26 Topical administration of oxazolidinones for transdermal delivery

Publications (2)

Publication Number Publication Date
NO20006161L NO20006161L (no) 2000-12-04
NO20006161D0 true NO20006161D0 (no) 2000-12-04

Family

ID=22210475

Family Applications (1)

Application Number Title Priority Date Filing Date
NO20006161A NO20006161D0 (no) 1998-06-05 2000-12-04 Topisk tilförsel av oksazolidinoner for transdermal levering

Country Status (28)

Country Link
US (2) US6613349B2 (de)
EP (1) EP1083900B1 (de)
JP (1) JP2002516852A (de)
KR (1) KR100626781B1 (de)
CN (1) CN1168447C (de)
AT (1) ATE220548T1 (de)
AU (1) AU749523B2 (de)
BR (1) BR9910318A (de)
CA (1) CA2327326A1 (de)
CO (1) CO5011042A1 (de)
CZ (1) CZ292420B6 (de)
DE (1) DE69902170T2 (de)
DK (1) DK1083900T3 (de)
EA (1) EA003699B1 (de)
ES (1) ES2179658T3 (de)
HU (1) HU225234B1 (de)
ID (1) ID23775A (de)
IL (1) IL139843A0 (de)
MY (1) MY122454A (de)
NO (1) NO20006161D0 (de)
NZ (1) NZ508636A (de)
PL (1) PL193535B1 (de)
PT (1) PT1083900E (de)
SK (1) SK285352B6 (de)
TR (1) TR200003205T2 (de)
TW (1) TWI224000B (de)
WO (1) WO1999062504A2 (de)
ZA (1) ZA200005886B (de)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9928568D0 (en) 1999-12-03 2000-02-02 Zeneca Ltd Chemical compounds
GB0009803D0 (en) 2000-04-25 2000-06-07 Astrazeneca Ab Chemical compounds
US6562820B2 (en) * 2000-07-05 2003-05-13 Pharmacia & Upjohn Company Method for treatment and prevention of mastitis
WO2003030906A1 (en) * 2001-10-11 2003-04-17 Pharmacia & Upjohn Company Treating infections by administration of oxazolidinones to the skin
PL372661A1 (en) * 2002-03-29 2005-07-25 Pharmacia & Upjohn Company Llc. Parenteral, intravenous, and oral administration of oxazolidinones for treating diabetic foot infections
US20060222692A1 (en) * 2005-03-31 2006-10-05 Fairfield Clinical Trials Llc Method and compositions for transdermal administration of antimicrobial medications
CN112409285A (zh) * 2020-11-30 2021-02-26 山东金城昆仑药业有限公司 噁唑烷酮类化合物的晶型及其制备方法和应用

Family Cites Families (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3743727A (en) 1970-11-16 1973-07-03 Crown Zellerbach Corp Enhancing tissue penetration of certain antimicrobial agents with dimethyl sulfoxide
US4507287A (en) 1983-06-20 1985-03-26 Dixon Glen J Preparation and method for the treatment of acne
JP2558107B2 (ja) 1986-12-18 1996-11-27 第一製薬株式会社 外用剤
US4943435A (en) 1987-10-05 1990-07-24 Pharmetrix Corporation Prolonged activity nicotine patch
US4960771A (en) 1988-07-12 1990-10-02 Rajadhyaksha Vithal J Oxazolidinone penetration enhancing compounds
US5254577A (en) * 1988-07-29 1993-10-19 The Du Pont Merck Pharmaceutical Company Aminomethyloxooxazolidinyl arylbenzene derivatives useful as antibacterial agents
US5164510A (en) 1988-09-15 1992-11-17 The Upjohn Company 5'Indolinyl-5β-amidomethyloxazolidin-2-ones
US5231188A (en) 1989-11-17 1993-07-27 The Upjohn Company Tricyclic [6.5.51]-fused oxazolidinone antibacterial agents
US5143928A (en) * 1990-03-27 1992-09-01 Warner-Lambert Company 3,5-di-tertiarybutyl-4-hydroxyphenylmethylene derivatives of 2-substituted thiazolidinones, oxazolidinones, and imidazolidinones as antiinflammatory agents
EP0610265B1 (de) 1991-11-01 1996-12-27 PHARMACIA & UPJOHN COMPANY Substituierte aryl- und heteroaryl-phenyloxazolidinone
TW203552B (en) * 1992-02-18 1993-04-11 J Baroody Lloyd Compositions of clindamycin and benzoyl peroxide for acne treatment
US5457194A (en) * 1993-03-17 1995-10-10 Abbott Laboratories Substituted aliphatic amine-containing macrocyclic immunomodulators
US5688792A (en) * 1994-08-16 1997-11-18 Pharmacia & Upjohn Company Substituted oxazine and thiazine oxazolidinone antimicrobials
NZ274966A (en) * 1993-11-22 1998-01-26 Upjohn Co Substituted-hydroxyacetyl piperazine phenyl oxazolidinone derivatives, use in pharmaceutical compositions
DE4425613A1 (de) 1994-07-20 1996-01-25 Bayer Ag 5-gliedrige Heteroaryl-oxazolidinone
DE4425612A1 (de) 1994-07-20 1996-04-04 Bayer Ag 6-gliedrige stickstoffhaltige Heteroaryl-oxazolidinone
ATE194281T1 (de) 1994-09-14 2000-07-15 Minnesota Mining & Mfg Matrix für transdermale wirkstofffreisetzung
US5604262A (en) * 1995-03-22 1997-02-18 Research Corporation Technologies, Inc. Topical antimicrobial agents
ZA968661B (en) * 1995-11-17 1998-04-14 Upjohn Co Oxazolidinone antibacterial agent with tricyclic substituents.
US5929086A (en) * 1996-05-10 1999-07-27 Pharmacia & Upjohn Company Topical administration of antimicrobial agents for the treatment of systemic bacterial diseases
JP2000510842A (ja) * 1996-05-10 2000-08-22 ファルマシア・アンド・アップジョン・カンパニー 全身性細菌疾患の治療のための抗菌剤の局所投与
US6040306A (en) * 1997-11-18 2000-03-21 Pharmacia & Upjohn Company Method of treating psoriasis, arthritis and reducing the toxicity of cancer chemotherapy
US6312715B1 (en) 1998-05-01 2001-11-06 3M Innovative Properties Company Adhesive microsphere drug delivery composition
US6174878B1 (en) * 1999-08-31 2001-01-16 Alcon Laboratories, Inc. Topical use of kappa opioid agonists to treat otic pain

Also Published As

Publication number Publication date
DK1083900T3 (da) 2002-11-04
WO1999062504A3 (en) 2000-02-24
CN1168447C (zh) 2004-09-29
CA2327326A1 (en) 1999-12-09
EA003699B1 (ru) 2003-08-28
AU749523B2 (en) 2002-06-27
WO1999062504A2 (en) 1999-12-09
EP1083900B1 (de) 2002-07-17
CN1298302A (zh) 2001-06-06
HK1036593A1 (en) 2002-01-11
SK285352B6 (sk) 2006-11-03
AU4184899A (en) 1999-12-20
TR200003205T2 (tr) 2001-05-21
EP1083900A2 (de) 2001-03-21
US7892574B2 (en) 2011-02-22
CZ20004432A3 (cs) 2001-03-14
SK16262000A3 (sk) 2001-06-11
HUP0102191A3 (en) 2003-07-28
PT1083900E (pt) 2002-12-31
ES2179658T3 (es) 2003-01-16
KR100626781B1 (ko) 2006-09-22
CZ292420B6 (cs) 2003-09-17
CO5011042A1 (es) 2001-02-28
KR20010052555A (ko) 2001-06-25
US20040072841A1 (en) 2004-04-15
US6613349B2 (en) 2003-09-02
PL345119A1 (en) 2001-12-03
IL139843A0 (en) 2002-02-10
NZ508636A (en) 2002-03-01
HU225234B1 (en) 2006-08-28
MY122454A (en) 2006-04-29
HUP0102191A2 (hu) 2002-05-29
JP2002516852A (ja) 2002-06-11
TWI224000B (en) 2004-11-21
US20020009483A1 (en) 2002-01-24
ZA200005886B (en) 2002-04-22
NO20006161L (no) 2000-12-04
EA200100010A1 (ru) 2001-06-25
ATE220548T1 (de) 2002-08-15
ID23775A (id) 2000-05-11
DE69902170D1 (de) 2002-08-22
BR9910318A (pt) 2001-01-30
PL193535B1 (pl) 2007-02-28
DE69902170T2 (de) 2003-03-13

Similar Documents

Publication Publication Date Title
US6337076B1 (en) Method and composition for the treatment of scars
EP1330221A4 (de) Medizinische zusammensetzungen, verbände und methoden zur behandlung von mikrobiellen infektionen von hautläsionen
BR9510423A (pt) Formulação lipossomal multilamelar de baixa rigidez processo de tratamento ou de profilaxia de uma infecção bacteriana em um animal e de uma variante mucoìde da mesma, uso da formulação lipossomal antibacteriana
ATE296093T1 (de) Azalid-antibiotika zur topischen behandlung oder vorbeugung okulärer infektionen
BRPI9908182C1 (pt) composições de proteína de matriz para cura de feridas
MXPA02002895A (es) Tratamiento topico de infecciones por estreptococcus.
AU4923500A (en) Device and method for increasing the transdermal permeation of medicaments
DE59906392D1 (de) Hyaluronatlyase als penetrationsförderer in topischen mitteln
NO20004282D0 (no) Matriksproteinpreparater for sÕrheling
RU2012149863A (ru) Полисахарид семени тамаринда для применения в лечении микробных инфекций
Nolting Non-traumatic removal of the nail and simultaneous treatment of onychomycosis
IL139843A0 (en) Topical administration of oxazolidinones for transdermal delivery
SG125079A1 (en) Oxazolidinones to treat eye infections
BR0007452A (pt) Uso de melagatrano ou de um derivado farmaceuticamente aceitável ou pró-droga do mesmo, método de tratamento de inflamação, e, formulação farmacêutica para uso no tratamento de inflamação
DK1135020T3 (da) Bipest-behandlinger
DE60207606D1 (de) Artikel zur wundbehandlung
Ljungberg Comparison of dextranomer paste and saline dressings for management of decubital ulcers
ES2104223T3 (es) 2-((2-(n-isobutil-n-metil)amino)-bencilsulfinil)bencimidazol como agente antimicrobiano contra helicobacter pylori.
ECSP992967A (es) Aplicación topica de oxazolidinonas para administracion transdermica
BR0014751A (pt) Composto, estereoisÈmero ou mistura de estereoisÈmeros, composição farmacêutica, método de tratamento de um paciente em necessidade de tratamento antimicrobiano, e, uso de um composto
Narang et al. Side effects of phenytoin: Case Series.
DK1150981T3 (da) Terapeutisk necleosidforbindelse
SE9903499D0 (sv) Antimicrobial agent for treatment and prophylaxis
CA3012299A1 (en) Debriding composition for treating wounds
RU99110181A (ru) Способ профилактики нагноения донорской раны после забора расщепленного кожного аутотрансплантата у больных с послеоперационными грыжами при наличии очагов хронической инфекции

Legal Events

Date Code Title Description
FC2A Withdrawal, rejection or dismissal of laid open patent application